Many people are used to thinking of arthritis as of the disease prevailing in people over 60. It is incorrect. Elderly people are thought to be mostly affected by the disease because if they have not got proper treatment in time, arthritis manifestation is really dreadf...

Rheumatoid arthritis (RA) is a chronic, systemic, autoimmune inflammatory disease that affects more than 2 million Americans. It is the subject of intense interest since it is so common and the lessons learned from it may help in the management of other forms of infl...

Biologics are a type of RA treatment that work by controlling the underlying disease itself in addition to the symptoms. Biologics act on the immune system. The cells of the immune system communicate using chemicals called cytokines. Experts believe that the reason...

Many people are used to thinking of arthritis as of the disease prevailing in people over 60. It is incorrect. Elderly people are thought to be mostly affected by the disease because if they have not got proper treatment in time, arthritis manifestation is really drea...

Rheumatoid arthritis (RA) is a chronic, progressive, autoimmune, inflammatory disease that affects more than 2 million Americans. It is a condition that is associated with increased mortality (rate of death) as a result of malignancy (lymphoma), cardiovascular events ...

Biologic therapy has revolutionized our approach to the treatment of rheumatoid arthritis (RA). Less than 10 years ago, the best we could hope for was to "modify disease" or slow it down and also help with symptoms. Now the goal is to not only control symptoms, it is ...

Rheumatoid arthritis is the most common inflammatory form of arthritis. It is a chronic, systemic autoimmune disease that affects more than 2 million Americans. The aim of therapy for this disease has been to help with symptoms, slow down progression, and possibly eff...

RA is a condition that forces half of patients to become disabled from the work force within five to ten years… and reduces life expectancy by as much as 18 years. RA affects about one per cent of the world’s adult population, most commonly women between the ages ...

For the past 12 years we have been extremely fortunate that the FDA-approved agents for treating MS have been extraordinarily safe. Similar degrees of safety are not seen among the medications available for treatment of most other autoimmune diseases. While we are gr...

Tokyo, Japan, Aug 5, 2005 - (JCNN JCNN - Japan Corporate News Network) - Eisai has received approval for an additional indication of its thrombolytic thrombolytic /throm·bo·lyt·ic/ (throm?bo-lit´ik) dissolving or splitting up a thrombus, or an agent that so ...

Tokyo, Japan, Sept 22, 2005 - (JCNN) - Abbott Japan has announced the results of its recent clinical study of Hokunalin Tape (tulobuterol), the company's proprietary ethical drug used in the treatment of bronchial bronchial /bron·chi·al/ (brong´ke-al) pertain...

Tokyo, Japan, Oct 19, 2006 - (JCN) - Sanko Junyaku Co., Ltd., Eisai Co., Ltd. and Fujirebio Inc. today announced their conclusion of a joint research agreement for development of a new KL-6 test kit consisting of an in-vitro, supplementary diagnostic marker for inter...

The U.S. District Court for the District of Maryland has granted a motion by Roche Diagnostics diagnostics /di·ag·nos·tics/ (di?ag-nos´tiks) the science and practice of diagnosis of disease. GmbH to compel IGEN to produce documents pertaining to IGEN's ...

Tokyo, Japan, Jan 22, 2007 - (JCN Newswire) - Eisai Co., Ltd. (TSE: 4523) announced today that on January 16 (U.K. time) the company's UK subsidiary Eisai Ltd. (Headquarters: London, Managing Director: Paul Hooper) received a marketing authorization approval for ...

Tokyo, Japan, Nov 20, 2006 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) announced today that on November 16 (U.K. time) the company's UK subsidiary Eisai Ltd. (Headquarters: London, Managing Director: Paul Hooper) receiv...

Tokyo, Japan, Apr 26, 2006 - (JCN Newswire) - Chugai Pharmaceutical Co., Ltd. (TSE: 4519) and F. Hoffmann-La Roche Ltd. (hereinafter "Roche") announced today that the humanized anti-human IL-6 (interleukin-6) receptor monoclonal antibody, Actemra(R) (generic name...

To the Editor: In some tropical areas, melioidosis, a disease caused by infection with Burkholderia pseudomallei, results in sepsis (1). This disease affects mostly adults with an underlying predisposing condition (2). With the increase in international travel, m...

Biologics are a type of RA treatment that work by controlling the underlying disease itself in addition to the symptoms. Biologics act on the immune system. The cells of the immune system communicate using chemicals called cytokines. Experts believe that the reaso...

Biologic therapy has revolutionized our approach to the treatment of rheumatoid arthritis (RA). Less than 10 years ago, the best we could hope for was to “modify disease� or slow it down and also help with symptoms. Now the goal is to not only control symptoms, i...

Rheumatoid arthritis (RA) is a chronic, progressive, autoimmune disease for which there is no current cure. However, the advent of biologic therapy has made it possible to induce remission in the majority of patients. However, in order to effect remission, researc...

RA is a condition that forces half of patients to become disabled from the work force within five to ten years… and reduces life expectancy by as much as 18 years. RA affects about one per cent of the world’s adult population, most commonly women between the ages...

Unlike osteoarthritis, which results from wear and tear on your joints, rheumatoid arthritis is an inflammatory condition. The exact cause of rheumatoid arthritis is unknown, but it's believed to be the body's immune system attacking the tissue that lines your joints...

Ankylosing spondylitis (AS) is a chronic, systemic, inflammatory form of arthritis that preferentially affects the spine leading to limitation of spine movement. The cause of AS is not fully known, but there is a strong genetic predisposition associated with a geneti...

Clinical Question ...

This study is currently recruiting patients. Sponsored by: Abbott Laboratories. The purpose of the study is to assess the long-term safety of adalimumab in subjects with moderate to severe chronic plaque psoriasis.</p> <pre> Condition Intervention Ph...

Abstract ...

Abstract ...

New-age Medication for Rheumatoid Arthritis With the advances in science and technology, we have seen a lot of progress in the field of medicine as well. Researchers and scientists have now come up with drugs and medications far superior than earlier avai...

Pain - Rheumatoid Arthritis - How to Decrease Pain and Inflammation Rheumatoid arthritis (RA), is a disease of primarily the child bearing years. It affects three times as many women as men and is particularly common between the ages of 25 and 50. "People...